Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

1. A compound of Formula (I)

wherein

R 1 and R 2 are independently H, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

L is a linker and selected from the group consisting of:

—(CH 2 ) m —X—,

—Y—(CH 2 ) n —X—,

and

wherein

X is selected from the group consisting of O, S, S(═O), and S(O) 2 , wherein L can be

 only when X is O,

Y is selected from the group consisting of O, NR 5 , S, S(═O), and S(═O) 2 ,

m is 2, or 3,

n is 2, 3, or 4,

t is 0 or 1,

p is 0, 1, 2, or 3,

q is 1, 2, 3, or 4,

wherein the sum of p and q is 1,2, 3, or 4;

Ar is selected from the group consisting of phenyl and a 6-membered heteroaryl ring containing up to three N atoms, said Ar being optionally substituted at any available position by 1 to 5 independently selected R 3 groups, and

optionally fused to a 5- or 6-membered saturated carbocyclic ring,

a 5- or 6-membered unsaturated carbocyclic ring, or

a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from the group consisting of N, O, and S,

wherein

said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R 4 groups;

R 3 is selected from the group consisting of:

hydroxy,

SH,

halo,

CN,

NO 2 ,

C(═O)OH,

C(═O)—OC 1 -C 6 alkyl,

CO(═O)—OC 3 -C 6 cycloalkyl,

NR 6 R 7 ,

C(═O)NR 6 R 7 ,

C(═S)NR 6 R 7 ,

C 1 -C 6 alkyl optionally substituted with halo, OH, NR 6 R 7 , or C 1 -C 6 alkoxy,

C 1 -C 6 haloalkyl,

C 1 -C 6 alkoxy,

C 1 -C 6 thioalkyl,

C 2 -C 6 alkenyl,

C 1 -C 6 haloalkoxy,

C 3 -C 8 cycloalkyl,

C 3 -C 8 cycloalkoxy,

phenoxy optionally substituted on the phenyl ring with halo, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy, and

a mono or bicyclic ring radical selected from the group consisting of

a) phenyl optionally fused to

a 5- or 6-membered saturated or partially unsaturated carbocylic ring, or

a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing from 1-3 heteroatoms selected from the group consisting of N, O, and S,

b) a 5- or 6-membered heterocyclic ring radical containing up to 4 heteroatoms selected from N, O, or S, optionally fused to

a 5- or 6-membered saturated or partially unsaturated carbocylic ring, or

a 5- or 6-membered saturated or partially unsaturated heterocyclic ring containing from 1-3 heteroatoms selected from the group consisting of N, O, and S,

said mono or bicyclic ring radical being optionally substituted with up to 5 groups independently selected from the group consisting of

halo,

hydroxy,

oxo,

CN,

C 1 -C 6 alkyl optionally substituted with halo, OH, NR 6 R 7 , or C 1 -C 6 alkoxy,

C 1 -C 6 haloalkyl,

C 1 -C 6 alkoxy,

C 1 -C 6 thioalkyl,

C 1 -C 6 haloalkoxy,

C 3 -C 8 cycloalkyl,

C 3 -C 8 cycloalkoxy,

C 1 -C 6 acyl,

C(═O)OH,

CH 2 C(═O)OH,

NR 6 R 7 ,

C(═O)NR 6 R 7 ,

C(═O)OC 1 -C 6 alkyl, and

C(═O)OC 3 -C 6 cycloalkyl;

R 4 is selected from the group consisting of:

oxo,

hydroxy,

halo,

CN

NR 6 R 7 ,

C 1 -C 6 alkyl optionally substituted with OH, NR 6 R 7 , or C 1 -C 6 alkoxy,

C 1 -C 6 haloalkyl,

C 1 -C 6 alkoxy,

C 1 -C 6 thioalkyl,

C 1 -C 6 haloalkoxy,

C 3 -C 8 cycloalkyl, and

C 3 -C 8 cycloalkoxy;

R 5 is selected from the group consisting of:

H,

C 1 -C 6 alkyl optionally substituted with C 3 -C 6 cycloalkyl,

C 1 -C 6 acyl,

benzyl optionally substituted with halo, C 1 -C 6 alkoxy, (C 1 -C 6 ) alkyl, CN, NH 2 , N[(C 1 -C 3 )alkyl] 2 , NO 2 , or CF 3 ,

C 3 -C 6 cycloalkyl, and

C(═O)OC 1 -C 6 alkyl;

R 6 and R 7 are independently selected from the group consisting of:

H,

C 1 -C 6 alkyl optionally substituted with C 3 -C 6 cycloalkyl,

C 1 -C 6 acyl,

benzyl optionally substituted with halo, C 1 -C 6 alkoxy, (C 1 -C 6 )alkyl, CN, NH 2 , N[(C 1 -C 3 )alkyl] 2 , NO 2 , or CF 3 ,

C 3 -C 6 cycloalkyl, and

phenyl optionally substituted with halo, C 1 -C 6 alkoxy, (C 1 -C 6 )alkyl, CN, N[(C 1 -C 3 )alkyl] 2 , NO 2 , or CF 3 ,

or

R 6 and R 7 may be taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocyclic ring optionally interrupted by NR 5 or O; and

pharmacologically acceptable esters and salts thereof.

2. The compound of claim 1 , wherein

R 1 and R 2 are independently H or C 1 -C 6 alkyl;

L is a linker and selected from the group consisting of:

—(CH 2 ) m —X—, and

—Y—(CH 2 ) n —X—,

wherein

X is selected from the group consisting of O, S, S(O), and S(O) 2 ,

Y is selected from the group consisting of O, NR 5 , S, S(═O), and S(═O) 2 ,

m is 2, or 3,

n is 2, 3, or 4;

Ar is a 6-membered heteroaryl ring containing up to three N atoms, optionally substituted at any available position by 1 to 5 independently selected R 3 groups, and

optionally fused to a 5- or 6-membered saturated carbocyclic ring,

a 5- or 6-membered unsaturated carbocyclic ring, or

a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from the group consisting of N, O, and S,

wherein

said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R 4 groups;

and

m, n, R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in claim 1 .

3. The compound of claim 1 , wherein

R 1 and R 2 are independently H or C 1 -C 6 alkyl;

L is —Y—(CH 2 ) n —X—,

wherein

X is O,

Y is O;

Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R 3 groups;

and

n, R 3 , R 6 , and R 7 are as defined in claim 1 .

4. The compound of claim 1 , wherein

R 1 and R 2 are independently H or C 1 -C 6 alkyl;

L is —Y—(CH 2 ) n —X—,

wherein

X is O,

Y is O;

Ar is phenyl optionally substituted at any available position by 1 to 5 independently selected R 3 groups;

and

fused to a 5- or 6-membered saturated carbocyclic ring, a 5- or

6-membered unsaturated carbocyclic ring, or a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from N, O, and S,

wherein

said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R 4 groups;

and

n, R 3 , R 4 , R 6 , and R 7 are as defined in claim 1 .

5. The compound of claim 1 , wherein

R 1 and R 2 are independently H or C 1 -C 6 alkyl;

L is —Y—(CH 2 ) n —X—,

wherein

X is O,

Y is NR 5 ;

Ar is a 6-membered heteroaryl ring containing up to three N atoms, optionally substituted at any available position by 1 to 5 independently selected R 3 groups; and

n, R 3 , R 5 , R 6 , and R 7 arc as defined in claim 1 .

6. The compound of claim 1 , wherein

R 1 and R 2 are independently H or C 1 -C 6 alkyl;

L is —(CH 2 ) m —X—,

wherein

X is O;

Ar is a 6-membered heteroaryl ring containing up to three N atoms, optionally substituted at any available position by 1 to 5 independently selected R 3 groups,

and

optionally fused to a 5- or 6-membered saturated carbocyclic ring,

a 5- or 6-membered unsaturated carbocyclic ring, or

a 5- or 6-membered heterocyclic ring containing up to 3 additional heteroatoms selected from N, O, and S,

wherein

said fused ring may be optionally substituted at any available position by 1 to 4 independently selected R 4 groups;

and

m, R 3 , R 4 , R 6 , and R 7 are as defined in claim 1 .

7. A compound selected from the group consisting oil

((1S)-5-{2-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]ethoxy}-2,3-dihydro-1H-inden-1-yl)acetic acid;

2-((1S)-5-{2-[6-(4-acetylphenyl)(2-pyridyl)]ethoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(3,7-dimethylbenzo[d]isoxazol-6-yloxy)propoxy]indanyl}acetic acid;

2-{(1S)-5-[3-(3-methyl-7-propylbenzo [d]isoxazol-6-yloxy)propoxy]indanyl}acetic acid;

2-{5-[2-(6-(2H-benzo[3,4-d]1,3-dioxolan-5-yl)(2-pyridyl))ethoxy](1S)indanyl}(2S)butanoic acid;

(2S)-2-((1S)-5-{2-[6-(4-ethylphenyl)(2-pyridyl)1]ethoxy}indanyl)butanoic acid;

2-[(1S)-5-(3-{[2-(4-ethylphenyl)-5-methylpyrimidin-4-yl]methylamino}propoxy) indanyl]acetic acid;

2-((1S)-5-{3-[(2-(21-1-benzo[3,4-d]1,3-dioxolen-5-yl)-5-methylpyrimidin-4-yl)methylamino]propoxy}indanyl)acetic acid;

2-[(1S)-5-[3-{2-methyl-4-[3-(trifluoromethyl)(1,2,4-thiadiazol-5-yl)]phenoxy}propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-({2-[4-(tert-butyl)phenyl]-5-methylpyrimidin-4-yl}methylamino) propoxylindanyl}acetic acid:

2-((1S)-5-{3-[2-propyl-4-(trifluoromethyl)phenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(methyl {5-methyl-2-[4-(methylethyl)phenyl]pyrimidin-4-yl}amino) propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{[2-(4-ethoxyphenyl)-5-methylpyrimidin-4-yl]methylamino}propoxy)indanyl]acetic acid;

2-[(1S)-5-(3-{[2-(4-ethoxyphenyl)-5-methylpyrimidin-4-yl]methylamino}propoxy)indanyl]acetic acid;

2-[(1S)-5-(3-{[5-fluoro-2-(4-methoxyphenyl)pyrimidin-4-yl]methylamino}propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-({5-fluoro-2-[4-(methylethyl)phenyl]pyrimidin-4-yl}methylamino) propoxylindanyl}acetic acid;

2-((1S)-5-{3-[(2-(2H-benzo [3,4-d]1,3-dioxolan-5-yl)-5-fluoropyrimidin-4-yl)methylamino]propoxy}indanyl)acetic acid;

((1S)-5-{3-[4-(4-ethyl-1,3-thiazol-2-yl)-2-propylphenoxy]propoxy}-2,3-dihydro-1H-inden-1-yl)acetic acid;

2-((1S)-5-{3-[4-(5-acetyl-4-methyl(1,3-thiazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-[(1S)-5-(3-{4-[4-(tert-butyl)(1,3-thiazol-2-yl)]-2-propylphenoxy}propoxy) indanyl]acetic acid;

2-(4-{3-[(1S)-1-(carboxymethyl)indan-5-yloxy]propoxy}-3-propylphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid;

2-[(1S)-5-(3-{2-propyl-4-[4-(trifluoromethyl)(1,3-thiazol-2-yl)]phenoxy}propoxy) indanyl]acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(4,5,6-trihydrocyclopenta[1,2-d]1,3-thiazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-(4-{3-[(1S)-1-(carboxymethyl)indan-5-yloxy]propoxy}phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid;

2-((1S)-5-{3-[4-(4,5-dimethyl(1,3-thiazol-2-yl))phenoxy]propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[4-(4-methoxy(1,3-thiazol-2-yl))phenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy(1,3-thiazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[4-(4,5-dimethyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(4,5,6-trihydrocyclopenta[1,2-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{2-methoxy-4-[4-(methylethoxy)(1,3-thiazol-2-yl)]phenoxy}propoxy)indanyl]acetic acid;

[(1S)-5-(3-{[5-(4,5-dimethyl-1,3-thiazol-2-yl)-2-pyridinyl]oxy}propoxy)-2,3-dihydro-1H-inden-1-yl]acetic acid;

2-[(1S)-5-{3-1,4-(4-ethyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(5-acetyl-4-methyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acctic acid;

2-((1S)-5-{3-[5-(5-acetyl-4-methyl(1,3-thiazol-2-yl))(2-pyridyloxy)]propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[5-(4-ethyl(1,3-thiazol-2-yl))(2-pyridyloxy)]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(4-(4,5,6,7-tetrahydrobenzoxazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S )-5-{3-[2-methoxy-4-(4-methoxy(1,3-thiazol-2-yl))phenoxy]propoxy}indanyl)acetic acid;

2-[(1S)-5-(3-{[2-(4-fluorophenyl)-6-methylpyrimidin-4-yl]methylamino]propoxy}indanyl)acetic acid;

2-[2-(4-{3-[(1S)-1-(carboxymethyl)indan-5-yloxyl]propoxy}-3-propylphenyl)-1,3-thiazol-4-yl]acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy-5-methyl(1,3-thiazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-((1S)-5-[3-{4-[5-(N,N-dimethylcarbamoyl)-4-methyl(1,3-thiazol-2-yl)]-2-propylphenoxy}propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(5,6,7-trihydro-2H-pyrano[2,3-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{[2-(4-cyclohexylphenyl)-6-methylpyrimidin-4-yl]methylamino}propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(4,5,6,7-tetrahydrobenzoxazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethyl(1,3-oxazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(4,5,6,7-tetrahydrobenzoxazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-[(1S)-5-(3-{4-[4-(methylethoxy)(1,3-thiazol-2-yl)]-2-propylphenoxy}propoxy)indanyl]acetic acid;

2-{(1S)-5-[3-(2-propyl-4-(1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(5-acetyl-4-methyl(1,3-oxazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-((1S)-5-{3-[4-(4-ethyl(1,3-oxazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-((1S)-5-{3-[4-(4-ethoxy-5-methyl(1,3-thiazol-2-yl))-2-methoxyphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(2-methoxy-4-(5,6,7-trihydro-2H-pyrano[2,3-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid;

2-{(1S)-5-[3-(4-phenoxy-2-propylphenoxy)propoxyl]indanyl}acetic acid;

2-((1S)-5-{3-[4-(5,5-dimethyl-7-oxo(4,5,6-trihydrobenzothiazol-2-yl))-2-propylphenoxy]propoxy}indanyl)acetic acid;

2-{(1S)-5-[3-(4-benzothiazol-2-yl-2-methoxyphenoxy)propoxy]indanyl}acetic acid;

2-{(1S)-5-[3-(2-ethoxy-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-{(1S)-5-[3-(2-propoxy-4-(4,5,6,7-tetrahydrobenzothiazol-2-yl)phenoxy) propoxy]indanyl}acetic acid;

2-{(1R)-5-[3-(2-propyl-4-(5,6,7-trihydro-2H-pyrano[2,3-d]1,3-thiazol-2-yl)phenoxy)propoxy]indanyl}acetic acid; and

[(1S)-5-({3-[4-(6,7-dihydro-5H-pyrano[3,2-d][1,3]thiazol-2-yl)-2-propylphenoxy]propyl}sulfanyl)-2,3-dihydro-1H-inden-1-yl]acetic acid.

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1 in combination with a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of claim 1 , in combination with a pharmaceutically acceptable carrier and one or more pharmaceutical agents.

10. The pharmaceutical composition of claim 9 , wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, anti-obesity agents, HMG CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, fibric acid derivatives, and anti-hypertensive agents.

11. A composition comprising an effective amount of one or more compounds of claim 1 in combination with an inert carrier.

12. A method of treating diabetes comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

13. A method of treating Syndrome X comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .

14. A method of treating diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

15. A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .

16. A method of treating cardiovascular diseases comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 , wherein said cardiovascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, coronary artery disease and hypertension.

17. A method of treating diabetes comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutical agents, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

18. The method of claim 17 , wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, and anti-obesity agents.

19. A method of treating Syndrome X comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutical agents.

20. The method of claim 19 , wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, and anti-obesity agents.

21. A method of treating diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutical agents, wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

22. The method of claim 21 , wherein said pharmaceutical agent is selected from the group consisting of PPAR agonists, sulfonylurea drugs, non-sulfonylurea secretagogues, α-glucosidase inhibitors, insulin sensitizers, insulin secretagogues, hepatic glucose output lowering compounds, insulin, and anti-obesity agents.

23. A method of treating diabetes, Syndrome or diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 in combination with one or more agents selected from the group consisting of HMG CoA reductase inhibitors, nicotinic acid, bile acid sequestrants, fibric acid derivatives, and anti-hypertensive agents, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes, and said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

24. The method of any one of claims 17 , 18 , 19 to 21 , 22 and 23 , wherein the compound of claim 1 and one or more pharmaceutical agents are administered as a single pharmaceutical dosage formulation.

25. A method of stimulating insulin secretion in a subject in need thereof by administering to said subject a compound of claim 1 .

26. Compounds according to claim 1 for the treatment of diabetes and diabetes-related disorders, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes, and said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

27. Medicaments containing at least one or more compounds according to claim 1 in combination with at least one pharmaceutically acceptable, pharmaceutically safe carrier or excipient.

28. Medicaments according to claim 27 for the treatment of diabetes, wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

29. A compound having the structure of

or a pharmaceutically acceptable salt thereof.

30. A method of treating diabetes comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 29 , wherein said diabetes is selected from the group consisting of type 1 diabetes, type 2 diabetes, maturity-onset diabetes of the young, latent autoimmune diabetes adult, and gestational diabetes.

31. A method of treating Syndrome X comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 29 .

32. A method of treating diabetes-related disorders comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 29 , wherein said diabetes-related disorder is selected from the group consisting of hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired fasting glucose, dyslipidemia, hypertriglyceridemia, and insulin resistance.

33. A method of treating obesity comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 29 .

34. A method of treating cardiovascular diseases comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of claim 29 , wherein said cardiovascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, coronary artery disease and hypertension.